SUTEZOLID AND TABLETS ARE NOW AVAILABLE We are happy to announce that the manufacturing of Sutezolid API and tablets for this study is now complete. Aurum and Sequella worked with the TB Alliance for the trial's Chemistry, Manufacturing and Control (CMC) work package. We would like to thank Professor Robert Wallis (Aurum), Dr Carol Nacy [...]
REGIMEN COULD BE THE FIRST TO MEET WHO CRITERIA The regimen we are proposing could be the first to meet the WHO criteria below for a pan-TB indication, being fully comprised of new agents unaffected by current resistance. Minimal Optimal Purpose Potential go/no-go decision point. Needed to achieve greater global impact. Indication 1st-line treatment [...]
REDUCING TB TREATMENT TO FOUR MONTHSOur trial, panTB-HM, responds to the Project to Accelerate New Treatments for Tuberculosis (PAN-TB). PAN-TB is a consortium of philanthropists seeking to accelerate the development of novel, shorter Tuberculosis treatments which are simpler to use and have better tolerability. panTB-HM, a phase 2c trial, will test Sutezolid at 2 dose [...]
